Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study.
Adult
Aged
Aged, 80 and over
Chemoradiotherapy, Adjuvant
/ methods
Combined Modality Therapy
Disease-Free Survival
Feasibility Studies
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ mortality
Netherlands
/ epidemiology
Organ Sparing Treatments
/ methods
Rectal Neoplasms
/ mortality
Transanal Endoscopic Microsurgery
/ methods
Treatment Outcome
Journal
JAMA surgery
ISSN: 2168-6262
Titre abrégé: JAMA Surg
Pays: United States
ID NLM: 101589553
Informations de publication
Date de publication:
01 01 2019
01 01 2019
Historique:
pubmed:
12
10
2018
medline:
26
11
2019
entrez:
11
10
2018
Statut:
ppublish
Résumé
Treatment of rectal cancer is shifting toward organ preservation aiming to reduce surgery-related morbidity. Short-term outcomes of organ-preserving strategies are promising, but long-term outcomes are scarce in the literature. To explore long-term oncological outcomes and health-related quality of life (HRQL) in patients with cT1-3N0M0 rectal cancer who underwent neoadjuvant chemoradiotherapy (CRT) followed by transanal endoscopic microsurgery (TEM). In this multicenter phase II feasibility study, patients with cT1-3N0M0 rectal cancer admitted to referral centers for rectal cancer throughout the Netherlands between February 2011 and September 2012 were prospectively included. These patients were to be treated with neoadjuvant CRT followed by TEM in case of good response. An intensive follow-up scheme was used to detect local recurrences and/or distant metastases. Data from validated HRQL questionnaires and low anterior resection syndrome questionnaires were collected. Data were analyzed from February 2011 to April 2017. The primary study outcome of the study was the number of ypT0-1 specimens by performing TEM. Secondary outcome parameters were locoregional recurrences and HRQL. Of the 55 included patients, 30 (55%) were male, and the mean (SD) age was 64 (39-82) years. Patients were followed up for a median (interquartile range) period of 53 (39-57) months. Two patients (4%) died during CRT, 1 (2%) stopped CRT, and 1 (2%) was lost to follow-up. Following CRT, 47 patients (85%) underwent TEM, of whom 35 (74%) were successfully treated with local excision alone. Total mesorectal excision was performed in 16 patients (4 with inadequate responses, 8 with completion after TEM, and 4 with salvage for local recurrence). The actuarial 5-year local recurrence rate was 7.7%, with 5-year disease-free and overall survival rates of 81.6% and 82.8%, respectively. Health-related quality of life during follow-up was equal to baseline, with improved emotional well-being in patients treated with local excision (mean score at baseline, 72.0; 95% CI, 67.1-80.1; mean score at follow-up, 86.9; 95% CI, 79.2-94.7; P = .001). Major, minor, and no low anterior resection syndrome was experienced in 50%, 28%, and 22%, respectively, of patients with successful organ preservation. In early-stage rectal cancer (cT1-3N0M0), CRT enables organ preservation with additional TEM surgery in approximately two-thirds of patients with good long-term oncological outcome and HRQL. This multimodality treatment triggers a certain degree of bowel dysfunction, and one-third of patients still undergo radical surgery and are overtreated by CRT.
Identifiants
pubmed: 30304338
pii: 2706186
doi: 10.1001/jamasurg.2018.3752
pmc: PMC6439861
doi:
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-54Commentaires et corrections
Type : CommentIn
Type : CommentIn
Références
Br J Surg. 2017 Jan;104(1):138-147
pubmed: 27706805
Lancet Oncol. 2015 Nov;16(15):1537-1546
pubmed: 26474521
Dis Colon Rectum. 2013 Dec;56(12):1349-56
pubmed: 24201388
Eur J Cancer. 1999 Feb;35(2):238-47
pubmed: 10448266
Eur J Surg Oncol. 2018 Feb;44(2):209-219
pubmed: 29275912
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Ann Surg. 2011 Jan;253(1):71-7
pubmed: 21135694
Colorectal Dis. 2012 Jul;14(7):797-803
pubmed: 21689340
Dis Colon Rectum. 2014 Nov;57(11):1253-9
pubmed: 25285691
Lancet Oncol. 2010 Sep;11(9):835-44
pubmed: 20692872
Dis Colon Rectum. 2007 Oct;50(10):1520-5
pubmed: 17674104
BMC Surg. 2011 Dec 15;11:34
pubmed: 22171697
Colorectal Dis. 2015 Nov;17(11):1011-7
pubmed: 26112651
Dis Colon Rectum. 2016 Apr;59(4):270-80
pubmed: 26953985
N Engl J Med. 2001 Aug 30;345(9):638-46
pubmed: 11547717
Br J Surg. 2016 Jul;103(8):1069-75
pubmed: 27146472
Dis Colon Rectum. 2011 Dec;54(12):1589-97
pubmed: 22067190
Lancet. 2017 Jul 29;390(10093):469-479
pubmed: 28601342
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
Ann Surg. 2007 May;245(5):726-33
pubmed: 17457165
Dis Colon Rectum. 2014 May;57(5):585-91
pubmed: 24819098
Biometrics. 2000 Dec;56(4):971-83
pubmed: 11129494
Ann Surg. 2007 Nov;246(5):693-701
pubmed: 17968156
Dis Colon Rectum. 2013 Jan;56(1):6-13
pubmed: 23222274
BMC Cancer. 2015 Oct 23;15:767
pubmed: 26497495
Cancer Radiother. 2004 Oct;8(5):297-304
pubmed: 15561595
Surg Endosc. 2008 Feb;22(2):352-8
pubmed: 17943364
Br J Surg. 2013 Sep;100(10):1377-87
pubmed: 23939851
Br J Surg. 1982 Oct;69(10):613-6
pubmed: 6751457
Dis Colon Rectum. 2017 Oct;60(10):1032-1040
pubmed: 28891846
Ann Surg. 2012 May;255(5):922-8
pubmed: 22504191
PLoS One. 2015 Oct 27;10(10):e0141427
pubmed: 26505895
Br J Surg. 2015 Jun;102(7):853-60
pubmed: 25847025
J Natl Cancer Inst. 2016 Aug 10;108(12):
pubmed: 27509881
Lancet Oncol. 2015 Aug;16(8):919-27
pubmed: 26156652
Colorectal Dis. 2014 Jul;16(7):O223-33
pubmed: 24373460
J Clin Oncol. 2012 Jun 1;30(16):1926-33
pubmed: 22529255
Br J Cancer. 2017 Jan 17;116(2):169-174
pubmed: 27997526
Endoscopy. 2013 Oct;45(10):827-34
pubmed: 23884793
Radiother Oncol. 2005 Sep;76(3):234-40
pubmed: 16273666
Colorectal Dis. 2007 Jul;9(6):553-8
pubmed: 17573752